Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
← catalyst calendarNCT05842512 · readout in 499 d
Sponsored by Polaris Group (industry) · PII — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
60estimated
Sites
10
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-13 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Nonalcoholic Steatohepatitis (NASH)
Interventions
- Drug: ADI-PEG20 — also filed as Pegargiminase
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFDetermine Efficacy of ADI-PEG 20 vs Placebo in the treatment of fatty liver as assessed by change in hepatic fat fraction
measured 24 Weeks
Permalink · PII's whole pipeline · Catalyst calendar · Every registered study · What changed